Professor Trotman (University of Sydney) is a haematologist and Australian lymphoma clinician researcher and Head of Haematology at Concord Repatriation General Hospital NSW, where she was the Founding Director of the Clinical Research Unit 2005-2019. She leads a number of international trials collaborations and provides global leadership in charting the role of PET scanning in lymphoma.

She has led the global development of the BTK inhibitor Zanubrutinib in the treatment of Waldenström’s Macroglobulinaemia. She is the senior investigator in the Concord – Kirby Institute COVAX in lymphoma study with comprehensive humoral and cellular data informing ATAGI’s booster recommendations for the immune compromised.

Professor Trotman is committed to embedding research into clinical care as the founding Director (2004-2019) of the Concord Repatriation General Hospital Haematology Clinical Research Unit, New South Wales, Australia, with more than 800 patients recruited to >180 trials.

Professor Trotman mentors many emerging clinician researchers as the current Head of the Haematology Department at Concord, and as an experienced Principal Investigator. She is a past ALLG SAC member, and past Board member and Steering Committee member of the Australian Clinical Trials Alliance.

She is also committed to the implementation of research findings into practice, as evidenced by her successful MBS listing of PET for indolent lymphomas. Professor Trotman has also developed a number of digital practice and research initiatives in collaboration with colleagues and patients.

She is the Founder and Chair (2019-21) of Women in Lymphoma (WiL), an international alliance of lymphoma clinicians committed to advocacy and support of greater leadership of women in lymphoma teaching and research.